The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Sharon Elad*, Noam Yarom, Yehuda Zadik, Michal Kuten-Shorrer, Stephen T. Sonis

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations


Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.

Original languageAmerican English
Pages (from-to)57-77
Number of pages21
JournalCa-A Cancer Journal for Clinicians
Issue number1
StatePublished - 1 Jan 2022

Bibliographical note

Publisher Copyright:
© 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society


  • Antineoplastic Agents/adverse effects
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Humans
  • Mouth Mucosa/drug effects
  • Neoplasms/therapy
  • Oral Ulcer/diagnosis
  • Prevalence
  • Quality of Life
  • Radiation Injuries/diagnosis
  • Severity of Illness Index
  • Stomatitis/diagnosis


Dive into the research topics of 'The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies'. Together they form a unique fingerprint.

Cite this